In two (RCTs) the efficacy and safety of alemtuzumab were compared with interferon beta 1a (IFN) in people with RR-MS who were naïve to treatments (CARE-MS I) or had relapsed while taking IFN or glatiramer acetate (CARE-MS II) (94, 95). Here, IFNA1 is linked to myeloid sarcoma.